NUEDEXTA
NUEDEXTA is the world's first and only approved treatment for pseudobulbar affect (PBA). It is a combination of dextromethorphan hydrobromide, which acts on the central nervous system, and quinidine sulfate, which inhibits metabolism in order to increase the effective blood concentration of dextromethorphan. It is marketed by Avanir Pharmaceuticals, an affiliate in the U.S.
Sincerely Pharmaceutical Tech
Regards,
Client Success Team (CRM),
Please fill the all required fields....!!
Sincerely Packaging Labelling
